BENGALURU, India, March 27, 2026--(BUSINESS WIRE)--Biocon Limited (BSE: 532523; NSE: BIOCON) today announced the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, ...

Biocon Limited has entered into a global settlement and license agreement with Genentech, securing earliest licensed launch ...

New Delhi, Oct 14 (PTI) Biocon Ltd on Wednesday said it has entered into a global settlement and license agreement with Genentech for breast cancer drug Pebrilzo, its biosimilar to the reference produ ...

Biocon Limited’s (NSEI:BIOCON) most recent return on equity was a substandard 10.42% relative to its industry performance of 16.12% over the past year. Though BIOCON’s recent performance is ...

Biocon reaches global patent settlement with Genentech for its breast cancer biosimilar, Pebrilzo. Launches planned for EU/UK ...

Biotechnology major Biocon Ltd on Saturday said it has received a GST demand notice of over Rs 3.2 crore, including interest ...

Biocon Ltd will integrate Biocon Biologics Ltd as a wholly owned subsidiary in a deal valuing the unit at $5.5 billion, the company said on Saturday. Biocon will acquire the remaining stake in Biocon ...

On September 22, 2026, Biocon Biologics Limited (“Biocon”) announced that the European Medicines Agency’s (“EMA”) Committee for Medicinal Products ...

Biocon Electric has filed its DRHP with SEBI for a proposed IPO of up to 59 lakh shares, comprising a fresh issue and an ...

Biocon and Genentech executed the patent settlement agreement to resolve all pending disputes between the companies, ...